Zomelis-D 50/5 Tablet is a fixed-dose combination medication containing Dapagliflozin 5 mg and Vildagliptin 50 mg, indicated for the management of type 2 diabetes mellitus. Dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, promotes renal glucose excretion, thereby reducing plasma glucose levels independently of insulin secretion. Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances incretin hormone activity, leading to increased insulin release and decreased glucagon secretion in a glucose-dependent manner. The synergistic action of these agents provides improved glycemic control by targeting different pathophysiological mechanisms involved in type 2 diabetes. Zomelis-D is indicated as adjunctive therapy to diet and exercise to improve glycemic control in adults inadequately controlled on monotherapy or as initial combination therapy in appropriate patients. The combination is generally well tolerated; however, potential adverse effects include urinary tract infections, genital mycotic infections, hypoglycemia (especially when combined with insulin or sulfonylureas), and gastrointestinal disturbances. Caution is advised in patients with renal impairment, hepatic dysfunction, or a history of pancreatitis. Regular monitoring of renal function, glycemic parameters, and patient adherence is recommended to optimize therapeutic outcomes. Zomelis-D 50/5 Tablet offers an effective and convenient option for individualized diabetes management.